๐ SSRIs are considered a major first-line pharmacologic treatment for generalized anxiety disorder because of their effectiveness and favorable long-term safety profile.
๐ FDA-approved examples for GAD include escitalopram and paroxetine, although other SSRIs may be used off-label.
๐ SSRIs increase the availability of serotonin in the synaptic cleft by inhibiting its reuptake into presynaptic neurons.
๐ Improvement is gradual rather than immediate, and several weeks of consistent therapy can be required to achieve the full therapeutic response.
๐ Common adverse effects include nausea, headache, sleep disturbances, sexual dysfunction, and initial restlessness or anxiety.
๐ Clients should be taught not to abruptly discontinue SSRIs because sudden cessation can cause antidepressant discontinuation symptoms.
๐ Nurses should monitor for worsening depression, behavioral changes, and suicidal thoughts, particularly during initiation or dosage changes.
๐ Their effectiveness for both anxiety and frequently coexisting depressive symptoms makes SSRIs particularly useful for long-term GAD management.
๐ Serotonin-norepinephrine reuptake inhibitors (SNRIs) โ Correct
๐ SNRIs are also considered first-line pharmacologic treatments for GAD, with duloxetine and venlafaxine extended-release having FDA-approved GAD indications.
๐ These medications inhibit reuptake of serotonin and norepinephrine, increasing their availability within the central nervous system.
๐ Their therapeutic effects can decrease excessive worry, tension, restlessness, and other anxiety symptoms.
๐ Like SSRIs, SNRIs generally require consistent administration over several weeks rather than providing immediate anxiety relief.
๐ Common adverse effects can include nausea, insomnia, headache, sweating, and sexual dysfunction.
๐ Venlafaxine can increase blood pressure, particularly at higher doses, making periodic blood pressure monitoring important.
๐ Abrupt discontinuation can produce significant withdrawal/discontinuation symptoms, so prescribed tapering is generally necessary.
๐ SNRIs are especially useful when GAD occurs alongside depressive symptoms or certain chronic pain conditions.
๐ Buspirone โ Correct
๐ Buspirone is a nonbenzodiazepine anxiolytic with an FDA-approved indication for anxiety/GAD and acts primarily as a serotonin 5-HT1A receptor partial agonist.
๐ It is particularly useful for ongoing management of generalized anxiety rather than immediate treatment of an acute panic episode.
๐ Buspirone has a delayed therapeutic onset, with improvement generally developing after consistent administration rather than immediately after a dose.
๐ Unlike benzodiazepines, buspirone does not produce the same degree of sedation, tolerance, physical dependence, or misuse potential.
๐ Common adverse effects include dizziness, nausea, headache, and nervousness.
๐ Clients should understand that taking extra doses during periods of severe anxiety will not provide immediate relief.
๐ Consistent scheduled administration is important to maintain the medication's therapeutic effect.
๐ Its low dependence potential makes buspirone particularly valuable when long-term anxiety treatment is required.
๐ Benzodiazepines โ Correct
๐ Several benzodiazepines have FDA-approved anxiety indications and can provide rapid relief of significant anxiety symptoms.
๐ These medications enhance the inhibitory effects of GABA, decreasing central nervous system excitability.
๐ Their relatively rapid onset of action distinguishes them from SSRIs, SNRIs, and buspirone.
๐ Examples include alprazolam, lorazepam, and diazepam, although specific FDA indications vary by medication.
๐ Major adverse effects include sedation, dizziness, impaired coordination, and cognitive slowing.
๐ Benzodiazepines carry risks of tolerance, physical dependence, misuse, and withdrawal, which limits their suitability for routine long-term GAD management.
๐ Abrupt discontinuation after sustained use can produce serious withdrawal manifestations, including rebound anxiety and seizures.
๐ Benzodiazepines therefore may have a role in selected clients but are generally not preferred as first-line long-term therapy for GAD.
๐ Tricyclic antidepressants (TCAs) โ Correct
๐ Some tricyclic antidepressants have anxiety-related FDA indications and can reduce anxiety through effects on serotonin and norepinephrine neurotransmission; FDA review materials include TCAs among antidepressants approved for GAD treatment.
๐ TCAs are generally not first-line therapy for GAD because newer medications have more favorable adverse-effect and safety profiles.
๐ Their adverse effects can include dry mouth, constipation, blurred vision, urinary retention, and sedation.
๐ Orthostatic hypotension can occur, increasing the risk for dizziness and falls.
๐ TCAs can also affect cardiac conduction, making overdose particularly dangerous.
๐ Baseline or follow-up ECG assessment may be appropriate for clients with cardiac risk factors.
๐ Clients should be monitored carefully for adverse effects and medication interactions during treatment.
๐ Their greater toxicity and anticholinergic burden help explain why SSRIs and SNRIs have largely replaced TCAs as preferred antidepressants for anxiety disorders.